Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1967 4
1968 10
1969 8
1970 15
1971 19
1972 14
1973 26
1974 30
1975 38
1976 58
1977 55
1978 55
1979 57
1980 72
1981 90
1982 85
1983 123
1984 194
1985 160
1986 166
1987 213
1988 201
1989 279
1990 279
1991 272
1992 311
1993 366
1994 372
1995 382
1996 393
1997 408
1998 460
1999 465
2000 523
2001 552
2002 599
2003 729
2004 746
2005 789
2006 924
2007 1016
2008 1092
2009 1162
2010 1286
2011 1370
2012 1523
2013 1751
2014 1812
2015 1836
2016 1864
2017 1744
2018 1848
2019 1972
2020 2179
2021 2237
2022 2158
2023 2002
2024 883

Text availability

Article attribute

Article type

Publication date

Search Results

34,788 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Malignant Genitourinary System Neoplasm"
Page 1
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, Taber A, Balcioglu M, Vang S, Assaf Z, Sharma S, Tin AS, Srinivasan R, Hafez D, Reinert T, Navarro S, Olson A, Ram R, Dashner S, Rabinowitz M, Billings P, Sigurjonsson S, Andersen CL, Swenerton R, Aleshin A, Zimmermann B, Agerbæk M, Lin CJ, Jensen JB, Dyrskjøt L. Christensen E, et al. J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6. J Clin Oncol. 2019. PMID: 31059311
In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated with disease recurrence (P = .023), whereas pathologic downstaging was not. Analysis of tumor-centric biomarkers showed that mutational …
In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated wi …
Testicular cancer update.
Adra N, Einhorn LH. Adra N, et al. Clin Adv Hematol Oncol. 2017 May;15(5):386-396. Clin Adv Hematol Oncol. 2017. PMID: 28591093 Review.
Pediatric genitourinary tumors.
Buckley KS. Buckley KS. Curr Opin Oncol. 2012 May;24(3):291-6. doi: 10.1097/CCO.0b013e32835265c9. Curr Opin Oncol. 2012. PMID: 22476187 Review.
PURPOSE OF REVIEW: We will review the 2010/2011 literature on pediatric genitourinary tumors and highlight the most significant publications. ...SUMMARY: In general, the prognosis for patients with pediatric genitourinary tumors is favorable. Further understanding o …
PURPOSE OF REVIEW: We will review the 2010/2011 literature on pediatric genitourinary tumors and highlight the most significant publi …
PET/CT Limitations and Pitfalls in Urogenital Cancers.
Vasireddi A, Nguyen NC. Vasireddi A, et al. Semin Nucl Med. 2021 Nov;51(6):611-620. doi: 10.1053/j.semnuclmed.2021.06.013. Epub 2021 Jul 6. Semin Nucl Med. 2021. PMID: 34243903 Review.
Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these t …
Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignan …
Recurrent hydatidiform moles.
Williams D, Hodgetts V, Gupta J. Williams D, et al. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):3-7. doi: 10.1016/j.ejogrb.2010.01.003. Epub 2010 Feb 19. Eur J Obstet Gynecol Reprod Biol. 2010. PMID: 20171777 Review.
Prompt diagnosis, treatment and follow-up of patients using assays for betahCG from centres that specialise in this condition enable early diagnosis of potential malignant change. Hydatidiform moles occur quite frequently and although recurrence is rare, women who h …
Prompt diagnosis, treatment and follow-up of patients using assays for betahCG from centres that specialise in this condition enable early d …
Molecular imaging in cervical cancer.
Khan SR, Rockall AG, Barwick TD. Khan SR, et al. Q J Nucl Med Mol Imaging. 2016 Jun;60(2):77-92. Epub 2016 Feb 9. Q J Nucl Med Mol Imaging. 2016. PMID: 26859085 Free article. Review.
Uterine sarcoma 2008.
Lin JF, Slomovitz BM. Lin JF, et al. Curr Oncol Rep. 2008 Nov;10(6):512-8. doi: 10.1007/s11912-008-0077-9. Curr Oncol Rep. 2008. PMID: 18928666 Review.
Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For pati …
Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may …
Paediatric genitourinary cancers and late effects of treatment.
Sadak KT, Ritchey ML, Dome JS. Sadak KT, et al. Nat Rev Urol. 2013 Jan;10(1):15-25. doi: 10.1038/nrurol.2012.218. Epub 2012 Nov 27. Nat Rev Urol. 2013. PMID: 23183945 Review.
The most common childhood genitourinary cancers are Wilms tumour, rhabdomyosarcoma and germ cell tumour (GCT). ...However, the high cure rates have highlighted the need to minimize the long-term complications of treatments (referred to as 'late effects'), which can be caus …
The most common childhood genitourinary cancers are Wilms tumour, rhabdomyosarcoma and germ cell tumour (GCT). ...However, the high c …
Prostate Cancer Prevention: Concepts and Clinical Trials.
Hamilton Z, Parsons JK. Hamilton Z, et al. Curr Urol Rep. 2016 Apr;17(4):35. doi: 10.1007/s11934-016-0587-1. Curr Urol Rep. 2016. PMID: 26957512 Review.
There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhib …
There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatmen …
Latest progress in molecular biology and treatment in genitourinary tumours.
González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. González-Del-Alba A, et al. Clin Transl Oncol. 2020 Dec;22(12):2175-2195. doi: 10.1007/s12094-020-02373-z. Epub 2020 May 21. Clin Transl Oncol. 2020. PMID: 32440915 Review.
The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of d …
The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent …
34,788 results
You have reached the last available page of results. Please see the User Guide for more information.